Oncology Sales Drive Strong Quarter For Genentech
This article was originally published in The Pink Sheet Daily
Executive Summary
Avastin and Herceptin were each up more than 70% over the prior year’s quarter.
You may also be interested in...
FDA Approves Tarceva For Pancreatic Cancer
Supplemental NDA approval for Genentech/OSI’s erlotinib, previously approved for lung cancer, follows advisory committee recommendation.
Genentech/Biogen Idec Submit Rituxan sBLA For Rheumatoid Arthritis
Filing is second in two weeks for the biologic, following recent sBLA submission for front-line non-Hodgkin's lymphoma treatment.
Avastin Pricing Strategy, Expanded Indications Under Review At Genentech
Genentech may reconsider pricing forAvastin following "phenomenal" clinical trial results evaluating the biologic for first-line non-squamous non-small cell lung cancer and metastatic breast cancer